Cardiff Oncology shares plunge after Q2 earnings miss
Heather White, the Senior Vice President and Chief Legal Officer at Genpact Ltd (NYSE:G), recently sold 4,000 common shares of the company. The professional services firm has seen impressive momentum, with its stock delivering a 56% return over the past year and currently trading near its 52-week high of $56.76. According to InvestingPro analysis, the stock is showing signs of being overbought, though the company maintains a "GREAT" overall financial health score. The shares were sold at a price of $55.25 each, amounting to a total transaction value of $221,000. Following this sale, White retains ownership of 43,122 shares in the company. This transaction was reported in a Form 4 filing with the Securities and Exchange Commission, reflecting activity that took place on February 13, 2025. For deeper insights into Genpact’s valuation and 15+ additional exclusive ProTips, including management’s share buyback activities, visit InvestingPro.
In other recent news, Genpact Ltd has been the subject of several analyst upgrades following robust fourth-quarter results for 2024 and optimistic guidance for the fiscal year 2025. Mizuho (NYSE:MFG) Securities raised its price target for Genpact from $45 to $55, maintaining a neutral rating. BMO Capital Markets also increased its price target from $53 to $58, keeping a Market Perform rating. TD Cowen upgraded Genpact from ’Hold’ to ’Buy’ and increased the price target to $60, while Needham maintained a Buy rating and raised the price target to $65, and BofA Securities raised its price target from $52 to $58, preserving a ’Buy’ rating.
These revisions in price targets and ratings follow Genpact’s recent earnings report, where the company reported a fourth-quarter earnings per share (EPS) of $0.91 and revenue of $1.25 billion, exceeding consensus expectations. Genpact’s guidance for the first quarter of 2025 anticipates an EPS of $0.79-$0.80 and revenue projections of $1.202-1.213 billion. For the full fiscal year 2025, Genpact expects an EPS of $3.52-$3.59, with revenue forecasts ranging from $5.029 to $5.125 billion.
Genpact’s strong performance was seen particularly in its Data/Tech/AI and Digital Operations segments, contributing to the positive outlook. However, some analysts expressed reservations about the long-term sustainability of Genpact’s growth due to potential risks in its traditional Business Process Outsourcing (BPO) and the impact of generative AI on the company’s future growth trajectory. Despite these concerns, the recent developments indicate a positive trend for Genpact.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.